# Alkem share price today (Alkem Laboratories Ltd, NSE: ALKEM)

> Alkem share price today: ₹5,216.50 at the NSE close on 4 November 2026, down 8.0% in a year. Alkem Laboratories (NSE: ALKEM) is worth ₹62,365 crore, trades at a P/E of 27.4 and has closed between ₹4,947.00 and ₹5,836.50 over the past 52 weeks. > Alkem Laboratories Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ALKEM · Pharma - Formulators · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/alkem-laboratories-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹5,216.50 (−8.0% in a year)
- P/E: 27.4× (lower than 58% of the last 11 years)
- Revenue (Jun 2026): ₹3,740 Cr (+10.9% on a year ago)
- Profit (Jun 2026): ₹521 Cr (−22.0% on a year ago)
- Operating margin: 20.0% (−2.0 points on a year ago)
- ROCE: 21%, FY26
- Profit that came in as cash: 91%, last 3 years

The main question: domestic institutions moved +3.6 percentage points over 8 quarters while the business went the other way. ## What is the Alkem share price today? Alkem Laboratories Ltd's share price was ₹5,216.50 at the close on 4 November 2026. It has been falling for 5 weeks. That is 2.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹4,947 and ₹5,837, and at that close it sat 30% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. Over the last 11 years the share price moved +282% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Alkem this quarter? One change stood out: revenue up on a year earlier for 7 quarters in a row. 1. Revenue up on a year earlier for 7 quarters in a row In the June 2026 quarter revenue was ₹3,740 crore, +10.9% on a year earlier. Why: Revenue rose because branded India medicines grew at a double digit rate and smaller non-US markets grew fast. Trade generics were flat and US volumes were weak, but currency changes made US sales look better. Next results: check whether trade generics recover and help domestic growth. From the earnings call on 14 Aug 2026. ## What are Alkem's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Alkem reported revenue of ₹3,740 crore, up 10.9% from ₹3,371 crore a year earlier, and a profit of ₹521 crore, down 22.0% from ₹668 crore. ### Alkem results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹3,740 crore | ₹3,371 crore | +10.9% |
| Profit | ₹521 crore | ₹668 crore | −22.0% |
| Earnings per share | ₹43.49 | ₹55.56 | −21.7% |
| Operating margin | 20.0% | 22.0% | −2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Alkem's management discussed these results on a call held on 14 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Alkem share price history? Alkem closed at ₹5,216.50 on 4 November 2026, down 8.0% from ₹5,668.50 a year earlier (7 November 2025) and up 43.0% over five years. Its highest weekly close since March 2016 was ₹6,366.25 on 13 September 2024. ### Alkem share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹5,113.50 | +2.0% |
| 1 month ago · 1 Oct 2026 | ₹5,220.00 | −0.1% |
| 6 months ago · 8 May 2026 | ₹5,585.50 | −6.6% |
| 1 year ago · 7 Nov 2025 | ₹5,668.50 | −8.0% |
| 3 years ago · 3 Nov 2023 | ₹3,808.95 | +37.0% |
| 5 years ago · 4 Nov 2021 | ₹3,648.10 | +43.0% |
| 10 years ago · 4 Nov 2016 | ₹1,577.40 | +230.7% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹1,367.20 | +281.5% |
| Highest weekly close since March 2016 · 13 Sep 2024 | ₹6,366.25 | −18.1% |
| Lowest weekly close since March 2016 · 13 May 2016 | ₹1,186.45 | +339.7% |
| 52-week high (weekly close) · 16 Jan 2026 | ₹5,836.50 | −10.6% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹4,947.00 | +5.4% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Alkem? 4 Nov 2026: Alkem closed at ₹5,216.50, up 2.0% on the week and down 0.1% on the month. 14 Aug 2026: Alkem held its results call for April to June 2026. Management guided: India FY27 growth could end close to 12%; trade-generics growth of mid-single digits was described as acceptable over the next 1-2 years. ### Earlier

- 7 Aug 2026: ex-date for a dividend of ₹10 a share. - Results for April to June 2026: Revenue up 10.9% and profit down 22.0% on a year earlier. - 20 Feb 2026: ex-date for an interim dividend of ₹43 a share. ## What dividend does Alkem pay? Alkem paid ₹53 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 1.02% at the ₹5,216.50 close on 4 November 2026. The last was a dividend of ₹10 a share, ex-date 7 August 2026. ### Alkem dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 7 Aug 2026 | ₹10 | Dividend | same day |
| 20 Feb 2026 | ₹43 | Interim | same day |
| 8 Aug 2025 | ₹8 | Dividend | same day |
| 14 Feb 2025 | ₹37 | Interim | same day |
| 9 Aug 2024 | ₹5 | Dividend | 10 Aug 2024 |
| 16 Feb 2024 | ₹35 | Interim | 17 Feb 2024 |
| 10 Aug 2023 | ₹10 | Dividend | same day |
| 17 Feb 2023 | ₹40 | Interim + Special | 18 Feb 2023 |
| 8 Aug 2022 | ₹4 | Dividend | 10 Aug 2022 |
| 10 Feb 2022 | ₹30 | Interim | 12 Feb 2022 |
| 9 Aug 2021 | ₹5 | Dividend | 10 Aug 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Alkem Laboratories Ltd paid out 28% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Alkem management say on the latest results call? On the call for April to June 2026, held on 14 August 2026, Alkem's management guided: India FY27 growth could end close to 12%; trade-generics growth of mid-single digits was described as acceptable over the next 1-2 years. > “The OAI status of the Daman plant is a concern, but we do not see it impacting our business because nothing has stopped and the observations have been addressed.”
> Sandeep Singh, on the call for April to June 2026

### What management guided

- Gross margin maintained at 66.5-67% for the balance of FY27; API price increases expected to pressure later quarters. - US FY27 growth expected at high-single-digit to mid/high-single-digit, aided by currency; Daman OAI expected to have no business impact this year and resolve in 6-12 months. - Consolidated FY27 tax rate expected at approximately 30-32%; loss-making US S&G entities are not generating deferred tax assets. - Enzene US CDMO revenue expected to begin in FY28; break-even ruled out within the next 12 months, requiring annualized revenue of 25-30 million dollars; scale-up capital spending not expected this year. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/5824/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 14 August 2026.)

## What to watch in Alkem's next results? When Alkem reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Trade-generics primary sales recovery - check whether tighter DSO and inventory actions reverse the domestic growth drag. - What to check (from the call)
- Trade-generics primary sales recovery - check whether tighter DSO and inventory actions reverse the domestic growth drag. - Daman OAI remediation - check regulator progress and continued approved-product US supply without interruption. - Enzene US CDMO contract conversion - check whether commercial activity begins reducing the platform's operating drag. - Occlutech integration - check first consolidated contribution against the revised current-year plan. ## Which stock lists is Alkem on? Alkem is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 163](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 62371.52830742153](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Alkem profitable? Alkem Laboratories Ltd earned ₹521 Cr of net profit in the Jun 2026 quarter, −22.0% on the same quarter a year earlier. Full-year FY26 profit was ₹2,351 Cr. Over 10 years profit has grown 12.1% a year on average. That is 13.9% of the quarter's revenue. The same quarter a year earlier earned ₹668 Cr. For the full year, FY26 profit was ₹2,351 Cr (+6.1% on the year before). Why profit moved: revenue changed +10.9% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −7.8% and revenue +13.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Alkem make, and is it growing? Alkem Laboratories Ltd reported ₹3,740 Cr of revenue in the Jun 2026 quarter, +10.9% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 10 years it has grown 11.6% a year on average. The last full year, FY26, came in at ₹14,712 Cr. The last four reported quarters add to ₹15,081 Cr. FY26 revenue was ₹14,712 Cr, +13.5% on the year before. Recent pace: the last four quarters grew +13.4% on average, against 11.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +13.4%, against +8.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −5.5%, against +3.1% a year (rolling over). ## How much of every ₹100 of sales does Alkem keep? Alkem Laboratories Ltd's operating margin was 20.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 12.0% and 22.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.4 percentage points on the year while gross margin changed +2.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Alkem's profit turning into cash? Over the last 3 years, 91% of Alkem Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,963 Cr of operating cash against ₹2,351 Cr of profit. After ₹1,135 Cr of spending on assets, ₹828 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 91% of profit came in as cash: the cash cycle got 44 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 2.1× depreciation over three years. The next section checks what that spending is building. ## Where does Alkem's cash go? Alkem Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 152 days in FY26, down from 196 days in FY21. It spent ₹2,185 Cr on assets over the last 3 years. Customers take 74 days to pay, and stock sits for 239 days on average. At FY26 sales of ₹14,712 Cr, each day of that cycle ties up about ₹40.3 Cr, so roughly ₹6,127 Cr is tied up in the business at any time. FY26: customers took 74 days to pay and stock sat for 239 days, about 7.9 months of sales sitting as stock, for a full cycle of 152 days, shorter than FY21's 196. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 239 days. Customers pay about 74 days after that. Suppliers are paid at 161 days. Together that makes the 152-day cycle. Spending on assets: ₹2,185 Cr over the last 3 years, against ₹1,038 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹282 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Alkem's P/E ratio, and how does it compare with its own history? Alkem Laboratories Ltd's P/E is 27.4×, in the middle of its own history: higher than 42% of past readings. Its usual P/E (the middle reading) is 28.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹180.45. Why the multiple is where it is: over the past year earnings per share moved +6.3% while the price moved −8.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +7.4% a year; about +6.9% a year came from earnings growth and about +0.5 percentage points from the multiple (roughly no change); over 10 years the price moved +12.7% a year; about +10.9% a year came from earnings growth and about +1.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 5.6% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Alkem business getting better or worse? Alkem Laboratories Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 21.0%; each line tells part of the story. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Alkem earn on its capital? Alkem Laboratories Ltd earned a ROCE of 21% in FY26. That is up from a low of 12% in FY15. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 16.0% net margin and 0.71× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 16.0% net margin × 0.71× asset turnover × 1.51× leverage (assets divided by equity) ≈ 17.2% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 5.6% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Alkem have too much debt? Alkem Laboratories Ltd had ₹2,047 Cr of borrowings against ₹13,820 Cr of equity in FY26, so its debt is 0.15× its equity. Its operating profit is 19 times its interest bill. Over 5 years borrowings went from ₹1,707 Cr to ₹2,047 Cr. Over the last 3 of those years it spent ₹2,185 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 5.6% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Alkem shareholding pattern? Promoters cut their stake in Alkem Laboratories Ltd by 6.0 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 49.7% of the company. Domestic institutions moved +3.6 points over the same period, to 22.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −6.0 points over 8 quarters, to 49.7%; Domestic institutions: +3.6 points over 8 quarters, to 22.8%; Foreign institutions: +1.3 points over 8 quarters, to 10.3%. Why the owners changed: promoters drove it (−6.0 points), with the other side taken by domestic institutions (+3.6 points). They reduced their stake. ## How far is Alkem from balance-sheet trouble? For Alkem Laboratories Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Alkem rank in its industry? 47.6 out of 100, rank 24 of 44 in Pharma - Formulators, with 78% of the evidence available. Alkem Laboratories Ltd scores 47.6 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 24. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 14.2 + 17.4 + 11.9 + 4.1 = 47.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Alkem compared with? Alkem ranks 24 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 47.6 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.0/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18 + 11 + 12.3 = 71.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.5/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.5 + 9.1 + 18.6 = 70.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.4 + 11.2 + 8.6 = 69.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 7.1 + 10.5 = 69 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 20.4 + 16.1 + 2 = 66.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 8. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Most evidence points up · 74% evidence 65.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 18.3/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 18.3 + 6.3 + 11.9 = 65.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.7 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.3 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative
16. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
17. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.0 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.9 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 47.9 out of 100 Growth Capital Valuation Relative
24. Alkem Laboratories Ltd this page ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 13.4% · Profit -5.5% · Operating margin change -2 points · 83% evidence Capital efficiency 17.4/25 · ROCE 21.2% · Operating margin 20% · 76% evidence Valuation 11.9/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 4.1/20 · Lead over its industry -22.4% · Lead over NIFTY 500 -1.9% · 1 year -7.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.2 + 17.4 + 11.9 + 4.1 = 47.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.6 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 45.9 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.4 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 40.7 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.4 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 33.6 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Alkem in size? Alkem is the 10th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Aurobindo Pharma, Lupin and Glenmark Pharmaceuticals. Just below it: Biocon, Ipca Laboratories and Ajanta Pharma. ### Pharma - Formulators companies close in size

1. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) ₹96,744 crore
2. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) ₹91,962 crore
3. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) ₹64,875 crore
4. Alkem Laboratories Ltd ₹61,140 crore
5. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) ₹57,333 crore
6. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) ₹48,909 crore
7. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) ₹43,846 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Welspun Corp Ltd](https://www.sectoralpha.in/stocks/welspun-corp-ltd) ₹61,769 crore · DI Pipes/Saw Pipes
2. [L&T Finance Ltd](https://www.sectoralpha.in/stocks/l-t-finance-ltd) ₹61,256 crore · Conglomerate Backed NBFC
3. Alkem Laboratories Ltd ₹61,140 crore
4. [Bank of India](https://www.sectoralpha.in/stocks/bank-of-india) ₹60,487 crore · Banks - PSU
5. [APL Apollo Tubes Ltd](https://www.sectoralpha.in/stocks/apl-apollo-tubes-ltd) ₹60,116 crore · Steel - Tubes/Pipes

## What else do people ask about Alkem? ### What is Alkem's share price today? Alkem Laboratories Ltd's share price is ₹5,216.50, −8.0% over the past year. The whole company is worth ₹62,365 Cr on the market. In the last 52 weeks it traded between ₹4,947 to ₹5,837; today it is 30% of the way up from the low, 2.9% below its 200-day average (as of 4 November 2026). ### What were Alkem's latest quarterly results? Alkem Laboratories Ltd reported revenue of ₹3,740 Cr and net profit of ₹521 Cr for the Jun 2026 quarter. Revenue rose 10.9% and profit fell 22.0% compared with a year earlier. Earnings per share were ₹43.49. The operating margin was 20.0%, 2.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is Alkem's market cap? Alkem Laboratories Ltd's market capitalisation is ₹62,365 Cr at a share price of ₹5,216.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Alkem performing? Alkem Laboratories Ltd's share price has been falling for 5 weeks. In its latest quarter, revenue rose 10.9% and profit fell 22.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 4 November 2026). ### Will Alkem's share price go up? This page does not forecast Alkem Laboratories Ltd's share price. What it shows instead: the share price is ₹5,216.50, and it has been falling for 5 weeks. Its P/E of 27.4× is higher than 42% of its own last 11 years (as of 4 November 2026). ### Who owns Alkem? Promoters own 49.7% of Alkem Laboratories Ltd, foreign institutions 10.3%, domestic institutions 22.8% and the public 17.1% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 6.0 percentage points over 8 quarters (as of 4 November 2026). ### Where is Alkem in its business cycle? Alkem Laboratories Ltd's FY26 operating margin was 20.0%, against a 13-year range of 12.0% to 22.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 20.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Alkem story? The main question: domestic institutions moved +3.6 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Alkem a stock worth studying right now? What the numbers show: Alkem Laboratories Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Alkem share price forecast for 2026? What management itself guided: India FY27 growth could end close to 12%; trade-generics growth of mid-single digits was described as acceptable over the next 1-2 years. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.